{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:49:33Z","timestamp":1792079373193,"version":"4.4.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD). Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremelanotide injection, Vyleesi, and melanocortin 4 receptor agonist between January 1, 1996, and December 15, 2019. Reference lists from included articles were also reviewed for pertinent citations. Study Selection\/Data Extraction: We included phase 2 and 3 trials of bremelanotide. There were 2 reports of phase 3 trials and 2 reports of phase 2 trials. Additional information from supplementary analyses was also referenced. Data Synthesis: Bremelanotide demonstrates significant improvement in desire and a significant decrease in distress related to lack of desire. The most common adverse effects include nausea (39.9%), facial flushing (20.4%), and headache (11%). Relevance to Patient Care and Clinical Practice: Bremelanotide is the second Food and Drug Administration\u2013approved medication for the treatment of HSDD. Bremelanotide\u2019s place in therapy is unknown, as the HSDD guidelines were last updated in 2017. Although the trials met statistical significance for change in sexual desire elements and distress related to sexual desire, the clinical benefit may only be modest. Conclusion: Bremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity. Bremelanotide is safe and has limited drug-drug interactions, including no clinically significant interactions with ethanol. Prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month. Individuals should discontinue use after 8 weeks without benefit.<\/jats:p>","DOI":"10.1177\/1060028019899152","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T01:56:20Z","timestamp":1577930180000},"page":"684-690","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":39,"title":["Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder"],"prefix":"10.1177","volume":"54","author":[{"given":"Danielle","family":"Mayer","sequence":"first","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5132-5313","authenticated-orcid":false,"given":"Sarah E.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"bibr1-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.09.018"},{"key":"bibr2-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2017.01.004"},{"key":"bibr3-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01187-w"},{"key":"bibr4-1060028019899152","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.518114"},{"key":"bibr5-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2017.11.008"},{"key":"bibr6-1060028019899152","unstructured":"Addyi (Flibanserin) [package insert]. Raleigh, NC: Sprout Pharmaceuticals; 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022526lbl.pdf. Accessed December 4, 2019."},{"key":"bibr7-1060028019899152","unstructured":"Vyleesi (Bremelanotide) [package insert]. Waltham, MA: AMAG Pharmaceuticals Inc; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210557s000lbl.pdf. Accessed December 4, 2019."},{"key":"bibr8-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001221"},{"issue":"2","key":"bibr9-1060028019899152","first-page":"283","volume":"1","author":"Koplowitz LP","year":"2018","journal-title":"JACCP"},{"issue":"2","key":"bibr10-1060028019899152","first-page":"283","volume":"1","author":"Koplowitz LP","year":"2018","journal-title":"JACCP"},{"key":"bibr11-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.018"},{"key":"bibr12-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00268.x"},{"key":"bibr13-1060028019899152","doi-asserted-by":"publisher","DOI":"10.2217\/whe-2016-0018"},{"key":"bibr14-1060028019899152","first-page":"A30","volume":"26","author":"Kingsberg S","year":"2017","journal-title":"J Womens Health"},{"key":"bibr15-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(17)31236-1"},{"key":"bibr16-1060028019899152","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1089\/jwh.2016.5859","volume":"26","author":"Althof S","year":"2017","journal-title":"J Womens Health"},{"issue":"4","key":"bibr17-1060028019899152","first-page":"A36","volume":"26","author":"Kroll R","year":"2017","journal-title":"J Womens Health"},{"key":"bibr18-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000533378.89365.bd"},{"key":"bibr19-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000533221.21767.0a"},{"key":"bibr20-1060028019899152","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000559073.00208.e2"},{"key":"bibr21-1060028019899152","unstructured":"Medi-Span Online. Bremelanotide. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc; December 3, 2019."},{"key":"bibr22-1060028019899152","unstructured":"Medi-Span Online. Flibanserin. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc; December 3, 2019."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019899152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019899152","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019899152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:23Z","timestamp":1777374923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019899152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/1060028019899152"],"URL":"https:\/\/doi.org\/10.1177\/1060028019899152","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}